Date: 2015-09-15
Type of information: Nomination
Compound:
Company: Pfenex (USA - CA)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On September 15, 2015, Pfenex, a clinical-stage biosimilars company, announced that Dennis M. Fenton, Ph.D., has been appointed to the company\'s board of directors, deepening the manufacturing and product development expertise of the biosimilar company. Dr. Fenton, an industry pioneer, has over three decades of experience in the biotechnology industry. Dr. Fenton retired after a lengthy and distinguished career with Amgen, where he held a variety of notable roles, including Executive Vice President, Operations. Prior to Amgen, he was a senior researcher with Pfizer. Dr. Fenton most recently served on the board of directors of Hospira, Dendreon Corporation, Genzyme and Amira Pharmaceuticals. Dr. Fenton is an alumnus of Rutgers University, where he graduated with a Ph.D. in microbiology. He currently serves as a member of the board of directors for Portola Pharmaceuticals, XenoPort, Nora Therapeutics and Kythera Biopharmaceuticals.
Financial terms:
Latest news:
